33 terminated. 33 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Terminated 33 |
| Phase 1 | 7 | Terminated 7 |
| Phase 3 | 1 | Terminated 1 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| 3-D Super Resolution Ultrasound Microvascular Imaging Definity, Acoustic Angiography - Breast Cancer, Thyroid Cancer | Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 27 | 2022-05-26 | 2025-10-06 |
| IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC Pembrolizumab - Thyroid | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2022-02-11 | 2026-03-23 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| Anti-VEGF Therapy for Acute Thyroid Eye Disease Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone - Thyroid Eye Disease | Phase 2 | Terminated | Massachusetts Eye and Ear Infirmary | 8 | 2020-11-02 | 2026-10-20 |
| Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Artificial Tears - Thyroid Carcinoma, Radioactive Iodine Level | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 9 | 2020-10-05 | 2024-01-18 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection) - Graves' Ophthalmopathy (GO) | Phase 2 | Terminated | Immunovant Sciences GmbH | 65 | 2019-07-23 | 2022-09-22 |
| Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab, Tremelimumab - Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 79 | 2019-04-02 | 2026-03-11 |
| Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Lenvatinib - Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma | Phase 2 | Terminated | Emory University | 4 | 2019-01-16 | 2022-11-10 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET) - Thyroid Gland Carcinoma | Phase 2 | Terminated | University of California, San Francisco | 12 | 2018-03-19 | 2021-06-29 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer ETBX-011, ALT-803 - Thyroid Cancer, Colon Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 3 | 2017-06-26 | 2024-08-06 |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2017-06-19 | 2021-09-27 |
| Celecoxib for Thyroid Eye Disease Celecoxib, artificial tears - Thyroid Eye Disease | Phase 2 | Terminated | Johns Hopkins University | 7 | 2017-03-05 | 2020-07-31 |
| Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers Metformin Hydrochloride, Radioactive Iodine, Placebo - Thyroid | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 13 | 2017-01-05 | 2025-12-11 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer CUDC-907 - Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2016-12-22 | 2018-12-21 |
| Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study gemcitabine -oxaliplatine combination - Thyroid Cancer | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 21 | 2016-04-07 | 2019-03-18 |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors eFT508 - Cancer | Phase 1 / Phase 2 | Terminated | Effector Therapeutics | 66 | 2015-12-03 | 2020-11-02 |
Showing 20 of 33. Sign in to see all of them.
Thyroid Neoplasms (22) · Carcinoma, Medullary (6) · Thyroid Cancer, Papillary (6) · Carcinoma, Non-Small-Cell Lung (5) · Graves Ophthalmopathy (5) · Thyroid Carcinoma, Anaplastic (5) · Breast Neoplasms (4) · Melanoma (4) · Neoplasms (4) · Adenocarcinoma, Follicular (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3)
Endocrine System Diseases (33) · Endocrine Gland Neoplasms (25) · Neoplasms by Site (25) · Head and Neck Neoplasms (22) · Neoplasms (22) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (17) · Carcinoma (15) · Adenocarcinoma (11) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (9) · Immune System Diseases (7)
Imatinib Mesylate (2) · Lubricant Eye Drops (2) · Sorafenib (2) · alectinib (2) · lenvatinib (2) · vandetanib (2) · ALT-803 (1) · Bevacizumab (1) · Bortezomib (1) · CUDC-907 (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1) · Dacarbazine (1) · Doxepin (1)
National Cancer Institute (NCI) (4) · Assistance Publique - Hôpitaux de Paris (2) · M.D. Anderson Cancer Center (2) · Aminex Therapeutics, Inc. (1) · Dana-Farber Cancer Institute (1) · Day One Biopharmaceuticals, Inc. (1) · Effector Therapeutics (1) · Emory University (1) · GlaxoSmithKline (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · Immunovant Sciences GmbH (1) · Ipsen (1) · Johns Hopkins University (1)
United States (27) · Spain (4) · France (3) · Australia (2) · Canada (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Bulgaria (1) · Egypt (1) · Germany (1) · India (1) · Israel (1)
Naris Nilubol, M.D. (2) · Arlene A. Forastiere, MD (1) · Christine H. Chung, M.D. (1) · Francis P Worden, MD (1) · James Gulley, M.D. (1) · James Yao, MD (1) · Jan Tennvall, MD, PhD (1) · Jaume Capdevila, M.D., Ph.D. (1) · Jeremy Barton, MD (1) · Joseph Curry, MD (1)
PMID 23113752, PMID 25086465, PMID 30297385, PMID 37816266, PMID 37917111, PMID 41935063, PMID 42826365
2004 (1), 2009 (1), 2018 (1), P30CA006973 (1), P30CA015083 (1), P50CA096784 (1), R01CA220681 (1), U01CA062502 (1)